FDA Takes A Second Look At Dr. Reddy's AmVaz, Will Re-Evaluate Norvasc Competitor
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency stays approval of product, which has a different salt than Pfizer's amlodipine, following questions about the source of data relied upon during review. Dr. Reddy's had been waiting for an appeals court decision on a patent before launching.